A circulating T_H2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29; PMID:25559415; https://doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74:2913-21; PMID:24840647; https://doi.org/10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama 2010; 304:1073-81; PMID:20823433; https://doi.org/10.1001/jama.2010.1275
   PubMed Web of Science ®Google Scholar
• Melisi D, Calvetti L, Frizziero M, Tortora G. Pancreatic cancer: systemic combination therapies for a heterogeneous disease. Curr Pharmaceutical Design 2014; 20:6660-9; PMID:25341938; https://doi.org/10.2174/1381612820666140826154327
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Remark R, Damotte D, Sautes-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014; 27:8-15; PMID:24487185; https://doi.org/10.1016/j.coi.2014.01.001
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; https://doi.org/10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19:1423-37; PMID:24202395; https://doi.org/10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; https://doi.org/10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014; 40:513-22; PMID:24315741; https://doi.org/10.1016/j.ctrv.2013.11.005
   PubMed Web of Science ®Google Scholar
• Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett 2014; 345:157-63; PMID:23879960; https://doi.org/10.1016/j.canlet.2013.07.014
   PubMed Web of Science ®Google Scholar
• Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004; 101:2727-36; PMID:15526319; https://doi.org/10.1002/cncr.20672
   PubMed Web of Science ®Google Scholar
• Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108:2063-9; PMID:23591198; https://doi.org/10.1038/bjc.2013.174
   PubMed Web of Science ®Google Scholar
• Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55:684-98; PMID:16094523; https://doi.org/10.1007/s00262-005-0047-0
   PubMed Web of Science ®Google Scholar
• Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer. Clin Cancer Res 2016; 22:2565-74; PMID:26719427; https://doi.org/10.1158/1078-0432.CCR-15-1732
   PubMed Web of Science ®Google Scholar
• Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 2015; 15:271-82; PMID:25882242; https://doi.org/10.1038/nri3831
   PubMed Web of Science ®Google Scholar
• Wormann SM, Diakopoulos KN, Lesina M, Algul H. The immune network in pancreatic cancer development and progression. Oncogene 2014; 33:2956-67; PMID:23851493; https://doi.org/10.1038/onc.2013.257
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; https://doi.org/10.1084/jem.20101876
   PubMed Web of Science ®Google Scholar
• De Monte L, Wormann S, Brunetto E, Heltai S, Magliacane G, Reni M, Paganoni AM, Recalde H, Mondino A, Falconi M et al. Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res 2016; 76:1792-803; PMID:26873846; https://doi.org/10.1158/0008-5472.CAN-15-1801-T
   PubMed Web of Science ®Google Scholar
• Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176:287-92; PMID:1613462; https://doi.org/10.1084/jem.176.1.287
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-96; PMID:20856220; https://doi.org/10.1038/ni.1937
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Niklasson L, Sandstrom P, Borch K, Druid H, Bratthall C, Messmer D, Larsson M, Spångeus A. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol 2011; 2011:212810; PMID:2190968; https://doi.org/10.1155/2011/212810
   PubMedGoogle Scholar
• Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surgical Res 2011; 167:e211-9; PMID:19765725; https://doi.org/10.1016/j.jss.2009.05.026
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676; https://doi.org/10.1158/1078-0432.CCR-06-0369
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, Yui R, Yamao J, Kim S, Kwon AH. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012; 41:409-15; PMID:22158072; https://doi.org/10.1097/MPA.0b013e3182373a66
   PubMed Web of Science ®Google Scholar
• Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, Yameen S, Carter RC, McKay CJ, Spoletini G, et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget 2014; 5:11064-80; PMID:25415223; https://doi.org/10.18632/oncotarget.2519
   PubMed Web of Science ®Google Scholar
• Lunardi S, Lim SY, Muschel RJ, Brunner TB. IP-10/CXCL10 attracts regulatory T cells: implication for pancreatic cancer. Oncoimmunology 2015; 4:e1027473; PMID:26405599; https://doi.org/10.1080/2162402X.2015.1027473
   PubMed Web of Science ®Google Scholar
• Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union against cancer and the american joint committee on cancer. Cancer 2010; 116:5336-9; PMID:20665503; https://doi.org/10.1002/cncr.25537
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-5; PMID:15405679; https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PloS One 2012; 7:e51862; PMID:23251644; https://doi.org/10.1371/journal.pone.0051862
   PubMed Web of Science ®Google Scholar